DEVELOPMENT COLLABORATION AGREEMENT



         This Development Collaboration Agreement ("AGREEMENT") is made and

effective as of June 10, 2003 (the "EFFECTIVE DATE"), by and between BioSeek,

Inc., a California corporation, having a place of business at 863-C Mitten Road,

Burlingame, California 94010 ("BIOSEEK") and Dynavax Technologies Corporation, a

Delaware corporation, having a place of business at 717 Potter Street, Suite

100, Berkeley, California 94710 ("DYNAVAX").



                                   BACKGROUND



         A.       BioSeek has developed certain technology known as BioMAP

Technology (as defined below) that is used to perform, among other things,

biofunctional characterization of genes and potential therapeutic compounds, as

further described in this Agreement;



         B.       Dynavax is engaged in research and development of certain

proprietary compounds for potential human therapeutic use, as further described

in this Agreement;



         C.       Dynavax and BioSeek desire that BioSeek apply the BioMAP

Technology to analyze and characterize the activity of certain compounds with

the objective of advancing the development of such compounds, and the parties

desire to enter into this Agreement to enable them to engage in such activities.



         Now, therefore, in consideration of the mutual covenants and conditions

contained herein, and intending to be legally bound, the parties agree as

follows:



         1. DEFINITIONS.



                  (a) "AFFILIATE" means, with respect to a particular party,

another person that controls, is controlled by or is under common control with

such party. For the purposes of the definition in this Section 1(a), the word

"control" (including, with correlative meaning, the terms "controlled by" or

"under the common control with") means the actual power, either directly or

indirectly through one or more intermediaries, to direct or cause the direction

of the management and policies of such entity, whether by the ownership of at

least fifty percent (50%) of the voting stock of such entity, or by contract or

otherwise.



                  (b) "BioMAP TECHNOLOGY" means BioSeek's proprietary human

cell-based model systems technology as more fully described in Exhibit 1(b).



                  (c) "CONFIDENTIAL INFORMATION" means, in the case of Dynavax,

information disclosed by Dynavax to BioSeek concerning the identity of the

Provided TZP Compounds, their development status, results of preclinical assays

and requirements for their handling and safety ("DYNAVAX CONFIDENTIAL

INFORMATION"), and in the case of BioSeek, information disclosed to Dynavax

concerning the BioMAP Technology or otherwise related to BioSeek's performance

of the Program ("BioSEEK CONFIDENTIAL INFORMATION"), that, in either case, if

disclosed in tangible form is marked "Confidential" or with other similar

designation to indicate its confidential or proprietary nature, or if disclosed

orally is indicated orally to be confidential or proprietary by the disclosing

party at the time of disclosure and is confirmed in writing as confidential or

proprietary by the disclosing party within a reasonable time after such

disclosure.



                  (d) "DERIVATIVE" means any compound that is derived from

another compound. As used in this Section 1(d), a compound shall be considered a

"Derivative" of a precursor compound if it either:



                           (1) is actually synthesized in a chemical synthesis

                               program based on the precursor compound; or



                                       1

{PAGE}



                           (2) is actually synthesized based on

                               structure-activity data relating to the precursor

                               compound; or



                           (3) was made in the course of further advancing one

                               or more precursor compounds toward

                               commercialization; or



                           (4) is included within the scope of any claim of a

                               patent application or patent which also claims

                               one or more precursor compounds and/or compounds

                               described in (1) through (3) above.



                  (e) "DYNAVAX PARTNER" means a third party with whom Dynavax

has entered into a Partnering Agreement.



                  (f) "FDA" means the United States Food and Drug

Administration.



                  (g) "IND" means an Investigational New Drug application, as

defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated

thereunder, for initiating clinical trials in the United States.



                  (h) "NET SALES" means the total amount invoiced to

non-Affiliate third parties on sales of TZP Products by Dynavax, Dynavax's

Partners, and the Affiliates and sublicensees of each, less the following

reasonable and customary deductions allowed to the buyer against the invoiced

amount: (i) trade, cash and quantity discounts; (ii) amounts for claims,

allowances or credits for returns; and (iii) prepaid freight, sales taxes,

duties and other governmental charges (including value added tax) on particular

sales, but excluding what is commonly known as income taxes, in each case if

charged separately on the invoice and paid by the customer. For the removal of

doubt, Net Sales shall not include sales to Dynavax, Dynavax's Partners, and the

Affiliates and sublicensees of each for resale; however, sales to such entities

shall be treated as Net Sales at list price. A "sale" shall also include a

transfer or other disposition for consideration other than cash, in which case

such consideration shall be valued at the fair market value thereof.



                  (i) "NOVEL MARKER" means a measurement or profile of a

biological or biochemical analyte that indicates the activity of one or more of

the TZP Compounds in a manner that is relevant to a mechanism of action of such

TZP Compound in a particular disease state, which measurement or profile has not

been, as of the date it is identified by BioSeek, or by Dynavax based on the

Profiling Results, (i) disclosed as a marker for such purpose in the public

domain as a result of prior publication or use, or (ii) identified as a marker

for such purpose by Dynavax without use of any Profiling Results, which Dynavax

shall have the burden of demonstrating with competent evidence.



                  (j) "PARTNERING AGREEMENT" means any agreement, arrangement or

understanding between Dynavax and a third party under which Dynavax grants to

the third party, directly or indirectly, any right or option to market, sell,

distribute or otherwise commercialize a TZP Product in any geographic territory.



                  (k) "PHASE III TRIAL" means that portion of the clinical

studies for the FDA submission and approval process which provides for trials of

a product on sufficient numbers of patients to establish the safety and efficacy

of such product to support regulatory approval in the proposed therapeutic

indication as more fully defined in 21 C.F.R. Section 312.21(c).



                  (l) "PROFILING RESULTS" means the profiling information

regarding the Provided TZP Compounds obtained as a result of BioSeek's

Home        Intelligence        Services        Subscriptions        News        About Us

Contact Us       Terms of Use       Resend Documents       Shopping Cart

Copyright © 2008 The Consus Group LLC